Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2015 Mar 12;21(6):1083–1090. doi: 10.1016/j.bbmt.2015.03.006

Figure 1. Improvement in skin tightness following imatinib therapy.

Figure 1

(A) Baseline. (B) After 6 months of treatment, there is increased pigmentation but marked reduction in rippled appearance of the skin (dose 200 mg daily). (C) End of active treatment (9 months), there is persistent pigmentation but overall marked improvement in ROM. (D) One year after ending active treatment, patient continues to have increased softening of skin fibrosis and reduction in hyperpigmentation (partial response, pt. 7).